Ines Breuksch
Overview
Explore the profile of Ines Breuksch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Breuksch I, Welter J, Bauer H, Enklaar T, Frees S, Thuroff J, et al.
Cell Commun Signal
. 2018 Jun;
16(1):35.
PMID: 29954386
Background: Loss of PTEN is involved in tumor progression of several tumor entities including renal cell carcinoma (RCC). During the translation process PTEN generates a number of splice variants, including...
2.
Kiweler N, Brill B, Wirth M, Breuksch I, Laguna T, Dietrich C, et al.
Arch Toxicol
. 2018 May;
92(7):2227-2243.
PMID: 29845424
Novel therapies are required for the treatment of metastatic renal cell carcinoma (RCC), which is associated with inoperable disease and patient death. Histone deacetylases (HDACs) are epigenetic modifiers and potential...
3.
Frees S, Breuksch I, Haber T, Bauer H, Chavez-Munoz C, Raven P, et al.
Oncotarget
. 2018 Apr;
9(21):15766-15779.
PMID: 29644008
Bone metastasis is an important prognostic factor in renal cell carcinoma (RCC). The calcium-sensing receptor (CaSR) has been associated with bone metastasis in several different malignancies. We analyzed the impact...
4.
Breuksch I, Prosinger F, Baehr F, Engelhardt F, Bauer H, Thuroff J, et al.
Oncotarget
. 2018 Jan;
8(64):107530-107542.
PMID: 29296184
The therapy of advanced renal cell carcinoma (RCC) is still a major challenge. To intervene therapeutically a deeper comprehension of the particular steps of metastasis is necessary. In this context...
5.
Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade
Ishibashi K, Haber T, Breuksch I, Gebhard S, Sugino T, Kubo H, et al.
Oncotarget
. 2017 Sep;
8(33):55230-55245.
PMID: 28903416
Metastatic renal cell carcinoma (RCC) is a tumor entity with poor prognosis due to limited therapy options. Tyrosine kinase inhibitors (TKI) represent the standard of care for RCCs, however a...
6.
Breuksch I, Weinert M, Brenner W
J Bone Oncol
. 2016 Oct;
5(3):143-145.
PMID: 27761377
This review summarizes the role of extracellular calcium, as found present in the bone tissue, in the process of bone metastasis.